Healthcare Investment Banking: Complete Industry Guide

Max

July 11, 2026

Share this post:

Healthcare investment banking is one of the most intellectually demanding and recession-resilient coverage groups in the industry. Healthcare spending accounts for nearly 18% of U.S. GDP, and the sector is driven by powerful structural tailwinds — aging populations, chronic disease prevalence, rapid innovation in biologics and medical devices, and massive government spending. For aspiring bankers who want to work on complex, high-stakes transactions with real-world impact, healthcare investment banking is an exceptional path.

In this comprehensive guide, we will cover everything you need to know about healthcare investment banking — from the major subsectors and valuation considerations to the top banks, deal types, and specific strategies for recruiting into healthcare groups.

What Is Healthcare Investment Banking?

Healthcare investment banking — sometimes referred to as HCG (Healthcare Group) — is a coverage group that advises companies across the healthcare ecosystem on M&A, IPOs, follow-on offerings, debt raises, and strategic alternatives. Healthcare bankers develop deep expertise in the regulatory environment, scientific pipelines, reimbursement dynamics, and commercial strategies that drive value in this sector.

What makes healthcare unique compared to other coverage groups is the sheer complexity of the industry. A healthcare banker needs to understand not just financial statements and valuation but also FDA approval processes, Medicare reimbursement policies, patent cliff dynamics, clinical trial data interpretation, and the competitive landscape among therapeutic areas. This intellectual depth is what attracts many top candidates to the group — and what makes it especially rewarding as a long-term career.

Key Healthcare Subsectors

Healthcare is a sprawling industry, and most banks divide coverage into several specialized subsectors. Understanding these divisions is critical both for recruiting and for performing well on the job.

Pharmaceuticals

Pharmaceutical companies develop, manufacture, and commercialize drugs. The pharma industry is dominated by large-cap companies like Pfizer, Johnson & Johnson, Merck, and AbbVie, which face constant pressure to replenish their pipelines as blockbuster drugs lose patent protection. This “patent cliff” dynamic drives enormous M&A activity, as pharma giants acquire smaller companies with promising drug candidates to fill revenue gaps. Bankers covering pharma need to understand drug development timelines, FDA regulatory pathways, and the economics of drug pricing and reimbursement.

Biotechnology

Biotech companies focus on developing novel therapeutics using biological processes — including gene therapies, cell therapies, monoclonal antibodies, and mRNA-based treatments. Many biotech firms are pre-revenue or pre-profit, which makes valuation especially challenging. Biotech bankers frequently work on IPOs for clinical-stage companies, follow-on offerings to fund drug development, and M&A transactions where large pharma companies acquire biotech firms for their pipeline assets. Understanding risk-adjusted net present value (rNPV) analysis is essential in this subsector.

Medical Devices and Diagnostics (MedTech)

MedTech companies develop surgical instruments, implantable devices, diagnostic equipment, and digital health tools. Major players include Medtronic, Abbott, Boston Scientific, Stryker, and Intuitive Surgical. The MedTech space has seen significant M&A consolidation as larger companies acquire innovative startups developing minimally invasive surgical tools, robotic surgery platforms, and AI-driven diagnostic technologies. Valuation in MedTech tends to rely more heavily on traditional earnings multiples compared to biotech, though growth-stage MedTech companies may trade on revenue multiples.

Healthcare Services

Healthcare services is a broad subsector covering hospitals, outpatient clinics, physician practice management companies, behavioral health providers, home health agencies, and healthcare staffing firms. Private equity has been extremely active in healthcare services, rolling up fragmented provider markets to create scale. If you enjoy understanding operational dynamics and working on PE-driven transactions, healthcare services is particularly interesting. Key metrics include same-store revenue growth, patient volume trends, payer mix, and EBITDA margins by service line.

Healthcare IT and Managed Care

Healthcare IT companies build electronic health records systems, revenue cycle management platforms, telehealth solutions, and data analytics tools. Managed care companies — the major health insurers like UnitedHealth, Anthem, and Cigna — are also covered by healthcare banking teams. These segments sit at the intersection of technology and healthcare, and deal activity often involves both strategic and financial buyers.

Key Metrics and Valuation in Healthcare Investment Banking

Healthcare valuation requires a versatile toolkit. The right approach depends heavily on the subsector and the company’s stage of development. If you are preparing for interviews, make sure you can walk through a DCF and explain how you would adapt it for different types of healthcare companies.

Comparable Company Analysis

For profitable healthcare companies — especially MedTech firms, healthcare services providers, and large pharma — EV/EBITDA and EV/Revenue multiples are standard. Understanding enterprise value vs. equity value is critical for getting these calculations right. Pharma companies often trade on P/E ratios adjusted for pipeline optionality, while healthcare services companies are valued on EV/EBITDA with careful adjustments for lease obligations and non-recurring items.

Risk-Adjusted NPV (rNPV) for Biotech

Pre-revenue biotech companies cannot be valued using traditional earnings or revenue multiples. Instead, bankers use risk-adjusted net present value (rNPV), which assigns probability-weighted values to each drug candidate in a company’s pipeline based on its stage of development. A Phase 3 drug candidate receives a much higher probability of approval than a Phase 1 asset. The rNPV framework accounts for the time value of money, the cost of ongoing clinical trials, and the expected commercial revenue upon approval.

Sum-of-the-Parts Analysis

Large diversified healthcare companies — think Johnson & Johnson or Abbott — are often valued using a sum-of-the-parts approach, where each business segment is valued separately using the most appropriate methodology and then aggregated. This technique is essential when a company operates across pharma, MedTech, and consumer health segments with very different growth and margin profiles.

Key Healthcare-Specific Metrics

Pipeline value: The aggregate risk-adjusted value of a pharma or biotech company’s drug development pipeline.
Total addressable market (TAM): The estimated market size for a drug, device, or service — critical for revenue projections.
Payer mix: The breakdown of a healthcare services company’s revenue by insurance type (commercial, Medicare, Medicaid, self-pay).
Patent expiry schedule: When key drug patents expire, triggering generic competition and revenue declines.
Same-store growth: Organic revenue growth from existing facilities, used for healthcare services and hospital companies.

Regulatory Considerations

Healthcare is one of the most heavily regulated industries in the world, and regulatory dynamics directly impact deal activity and valuation. Bankers in healthcare groups must understand:

FDA approval processes: The pathway from preclinical research through Phase 1, 2, and 3 clinical trials to FDA approval (or rejection). Accelerated approval pathways, breakthrough therapy designations, and priority review vouchers can all affect timelines and valuation.
FTC antitrust scrutiny: Large healthcare mergers face intense scrutiny from the Federal Trade Commission. Recent enforcement actions have blocked or restructured several major deals, particularly in pharmaceutical and healthcare services M&A.
Medicare and Medicaid reimbursement: Changes in government reimbursement rates can significantly impact healthcare services companies and MedTech firms. The Inflation Reduction Act’s drug pricing provisions have already affected pharma valuations.
Stark Law and Anti-Kickback Statutes: Regulations that restrict financial relationships between healthcare providers and referral sources. These laws affect deal structuring in healthcare services transactions.

Top Banks for Healthcare Investment Banking

Healthcare is a priority sector for most major investment banks. Here are the firms that consistently lead the league tables:

Bulge Bracket Leaders

Goldman Sachs, Morgan Stanley, and JPMorgan dominate large-cap healthcare M&A and IPO activity. These banks have dedicated healthcare teams with dozens of senior bankers covering each subsector. The compensation at these firms is top-tier, and the deal experience is broad.

Elite Boutiques

Centerview Partners, Lazard, and Evercore all maintain strong healthcare advisory practices. These firms tend to work on the largest and most complex strategic transactions, giving junior bankers direct exposure to senior decision-makers.

Healthcare-Focused Banks

Several banks have built specialized healthcare franchises. Leerink Partners (now SVB Leerink) is the dominant biotech advisory and capital markets franchise. Guggenheim Securities has a well-regarded healthcare practice. Piper Sandler, William Blair, and Raymond James are strong in mid-market healthcare transactions. These specialized banks can offer junior bankers more concentrated deal flow within specific healthcare subsectors.

Healthcare Investment Banking Interview Questions

If you are interviewing for a healthcare group, expect both standard technical questions and sector-specific questions. Here are some to prepare for:

How would you value a pre-revenue biotech company with two drug candidates in Phase 2 clinical trials?
What is risk-adjusted NPV, and how does it differ from a standard DCF?
A pharma company’s blockbuster drug is losing patent protection in two years. What strategic options would you advise?
How does the FDA approval process work, and how do approval probabilities change across clinical trial phases?
What are the key differences between valuing a MedTech company and a healthcare services company?
Why has private equity been so active in healthcare services?
Discuss a recent healthcare M&A transaction. What drove the deal, and how was the target likely valued?
How does the WACC for a clinical-stage biotech company differ from that of a large-cap pharma company?

Exit Opportunities from Healthcare Investment Banking

Healthcare bankers enjoy excellent exit opportunities, many of which are unique to the sector:

Healthcare-focused private equity: Firms like Welsh Carson, Danaher, and TPG Healthcare actively recruit from healthcare banking groups.
Life sciences venture capital: Biotech bankers are well-positioned for roles at healthcare-focused VC firms like OrbiMed, Versant Ventures, and ARCH Venture Partners.
Corporate development at pharma and MedTech companies: Companies like Pfizer, Medtronic, and Abbott have large corporate development teams staffed by ex-bankers.
Healthcare-focused hedge funds: Firms like Baker Brothers, RA Capital, and Perceptive Advisors hire analysts with deep healthcare sector knowledge.
Healthcare consulting: Specialized firms like LEK Consulting and Putnam Associates value the analytical skills and sector expertise of former healthcare bankers.

How to Recruit Into Healthcare Investment Banking

Breaking into healthcare investment banking requires demonstrating genuine sector interest alongside strong technical fundamentals. Here is what to focus on:

Build sector knowledge: Follow healthcare deal activity, read industry publications like BioPharma Dive and Fierce Biotech, and understand the major trends shaping the industry.
Leverage relevant coursework or experience: Pre-med coursework, life sciences research, or internships at healthcare companies can differentiate your candidacy. Even if you do not have a science background, taking the time to learn the basics of drug development and healthcare regulation will set you apart.
Network with healthcare bankers: Reach out to analysts and associates in healthcare groups at your target banks. Ask thoughtful questions about recent deals and sector trends. Our free course covers networking strategies that work.
Prepare a healthcare stock pitch: Pick a pharma, biotech, or MedTech company you find interesting. Build a simple model, understand the pipeline or product portfolio, and be ready to defend your investment thesis.

Whether you are coming from a target school or a non-target background, healthcare investment banking is accessible if you put in the work to develop genuine sector expertise. The combination of intellectual rigor, deal complexity, and exceptional exit opportunities makes it one of the most rewarding paths in investment banking.

For more on preparing for investment banking recruiting, check out our blog and free resources library.

Want Personalized Interview Coaching?

Wall Street Mastermind has helped over 2,100 students break into top investment banking roles. Whether you are targeting a healthcare group at Goldman Sachs, a biotech-focused boutique, or a healthcare PE fund, our coaches can help you prepare for every step — from building your resume and networking strategy to mastering technical interviews and sector-specific questions. Apply to work with us today.

Follow Wall Street Mastermind

Stay up to date with the latest investment banking recruiting tips, interview prep, and career advice:

Share this post:

About the Author

Max

Max Adams is the Head Coach of Wall Street Mastermind, the premier investment banking mentoring program. Max began his career in investment banking at Lazard and Qatalyst Partners -- two of the most prestigious advisory boutiques on Wall Street -- before moving into technology private equity at Vector Capital. Afterward, Max earned an MBA from Stanford GSB while completing a joint degree at the Harvard Kennedy School. Wall Street Mastermind has guided over 2,100 students into top finance careers since 2018. Connect with Max on LinkedIn or follow @wallstreetmastermind on Instagram.